Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer
In this study, we aim to explore the potential of Qi Ling decoction (QLD), a traditional Chinese medicine, in attenuating abiraterone resistance in prostate cancer. Cell viability and apoptosis were respectively measured by Cell Counting Kit-8 (CCK-8) assay and flow cytometry. The protein levels were assessed by Western blotting assay. Autophagosome formation was quantified by counting LC3 puncta. We found that QLD was capable of promoting abiraterone-induced apoptosis and cell death of PC3-AbiR and DU145-AbiR cells in vitro. A combination of QLD and abiraterone yielded a better tumor inhibition effect than QLD alone and a...
Source: Aging - December 21, 2022 Category: Biomedical Science Authors: Yigeng Feng Hongwen Cao Zixi Song Lei Chen Dan Wang Renjie Gao Source Type: research
Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer
In this study, we aim to explore the potential of Qi Ling decoction (QLD), a traditional Chinese medicine, in attenuating abiraterone resistance in prostate cancer. Cell viability and apoptosis were respectively measured by Cell Counting Kit-8 (CCK-8) assay and flow cytometry. The protein levels were assessed by Western blotting assay. Autophagosome formation was quantified by counting LC3 puncta. We found that QLD was capable of promoting abiraterone-induced apoptosis and cell death of PC3-AbiR and DU145-AbiR cells in vitro. A combination of QLD and abiraterone yielded a better tumor inhibition effect than QLD alone and a...
Source: Aging - December 21, 2022 Category: Biomedical Science Authors: Yigeng Feng Hongwen Cao Zixi Song Lei Chen Dan Wang Renjie Gao Source Type: research
Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change
Conclusions and recommendationsVariation across duplicated NMAs, together with reporting inadequacies, may compromise identification of best-performing treatments. Particularly in fast-moving fields, review authors should be aware of all relevant studies, and of other reviews with potential for overlap or duplication. We recommend that review protocols be published in advance, with greater clarity regarding the specific aims or scope of the project, and that reports include information on how the work builds upon existing knowledge. Source data and results should be clearly and completely presented to allow unbiased interp...
Source: Systematic Reviews - December 16, 2022 Category: International Medicine & Public Health Source Type: research
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study
ConclusionsWe observed a significant cost benefit in the upfront DOC group in Japanese real-world practice, while the PFS2 rates were similar between the groups. Upfront DOC was a more cost-effective option for men with mHSPC who were eligible for toxic chemotherapy. (Source: World Journal of Urology)
Source: World Journal of Urology - December 15, 2022 Category: Urology & Nephrology Source Type: research
HSD115 Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
The introduction of novel hormonal agents (NHAs) such as abiraterone acetate (ABI) and enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) was an important milestone given their survival benefits and tolerability relative to taxane chemotherapies. This descriptive study examined the utilization trends of NHAs in patients with mCRPC in the early years after approval in the province of Quebec in Canada. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: J Hu, A Aprikian, R Saleh, A Dragomir Source Type: research
Cardiac Biomarkers and Geriatric Assessment in Metastatic Castrate-Resistant Prostate Cancer During Abiraterone Acetate Therapy - A Cardio-Oncology Study
CONCLUSIONS: Age-adjusted D-dimer, and geriatric G8 scores may predict TTF in men with metastatic castration-resistant prostate cancer during AA therapy. These observations require further study in a larger population.PMID:36447439 | DOI:10.1177/10732748221140696 (Source: Cancer Control)
Source: Cancer Control - November 30, 2022 Category: Cancer & Oncology Authors: Micha ł Wilk Anna Wa śko-Grabowska Iwona Skoneczna Cezary Szczylik Sebastian Szmit Source Type: research
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?
Prostate Cancer and Prostatic Diseases, Published online: 29 November 2022; doi:10.1038/s41391-022-00617-3Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate? (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - November 29, 2022 Category: Urology & Nephrology Authors: Carsten-Henning Ohlmann Source Type: research
Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study
ConclusionsNo differences were observed between the treatment effects of chemotherapy and non-chemotherapy in patients with high-risk mCSPC after abiraterone acetate plus prednisone. These findings suggest that life-extending subsequent therapy after abiraterone acetate plus prednisone for mCSPC should be chosen at the physician ’s discretion and patient’s preference.Clinical Trial RegistrationClinicalTrials.gov, NCT01715285, registered 26 October, 2012. (Source: Targeted Oncology)
Source: Targeted Oncology - November 28, 2022 Category: Cancer & Oncology Source Type: research
Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
CONCLUSION: Over time, there was an increasing proportion of (1) patients who initiated NHAs without prior chemotherapy treatment, (2) NHA prescribing by urologists, and (3) ENZ users. Taken together, this implies that the introduction of NHAs has altered the management of mCRPC and urologists quickly adopted NHAs into their practice.PMID:36421333 | DOI:10.3390/curroncol29110680 (Source: Current Oncology)
Source: Current Oncology - November 24, 2022 Category: Cancer & Oncology Authors: Jason Hu Armen G Aprikian Ramy R Saleh Alice Dragomir Source Type: research
Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec
CONCLUSION: Over time, there was an increasing proportion of (1) patients who initiated NHAs without prior chemotherapy treatment, (2) NHA prescribing by urologists, and (3) ENZ users. Taken together, this implies that the introduction of NHAs has altered the management of mCRPC and urologists quickly adopted NHAs into their practice.PMID:36421333 | PMC:PMC9688923 | DOI:10.3390/curroncol29110680 (Source: Current Oncology)
Source: Current Oncology - November 24, 2022 Category: Cancer & Oncology Authors: Jason Hu Armen G Aprikian Ramy R Saleh Alice Dragomir Source Type: research
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review
CONCLUSIONS: This SLR of the Asian data on therapies for advanced PC from the pivotal and real-world studies confirms similar efficacy and safety outcomes, consistent with the results from the pivotal clinical trials. These findings will help clinicians make better treatment decisions in clinical practice for patients with advanced/metastatic PC.PMID:36407784 | PMC:PMC9666834 | DOI:10.1177/17588359221131525 (Source: Adv Data)
Source: Adv Data - November 21, 2022 Category: Epidemiology Authors: Marniza Saad Rainy Umbas Edmund Chiong Ravindran Kanesvaran Source Type: research
Efficacy and safety of therapies for advanced prostate cancer in Asia: Evidence from a systematic literature review
CONCLUSIONS: This SLR of the Asian data on therapies for advanced PC from the pivotal and real-world studies confirms similar efficacy and safety outcomes, consistent with the results from the pivotal clinical trials. These findings will help clinicians make better treatment decisions in clinical practice for patients with advanced/metastatic PC.PMID:36407784 | PMC:PMC9666834 | DOI:10.1177/17588359221131525 (Source: Adv Data)
Source: Adv Data - November 21, 2022 Category: Epidemiology Authors: Marniza Saad Rainy Umbas Edmund Chiong Ravindran Kanesvaran Source Type: research
